Cardiac endothelin and big endothelin in right-heart hypertrophy due to monocrotaline-induced pulmonary hypertension in rat

Cardiovascular Research

Volumn 44, Issue 1, 1999, Pages 197-206

  Brunner, Friedrich ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Endothelin; Hypertrophy

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ATRIAL NATRIURETIC FACTOR; BIG ENDOTHELIN 1; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN; MONOCROTALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR ENDOTHELIUM;

EID: 0033214092     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00155-8     Document Type: Article

References (48)

1. Baker K.M., Chernin M.I., Wixson S.K., Aceto J.F. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol. 259:1990;H324-H332.
2. Kojima M., Shiojima I., Yamazaki T., et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left-ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation. 89:1994;2204-2211.
3. Shubeita H.E., McDonough P.M., Harris A.N., et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. J Biol Chem. 265:1990;20555-20562.
4. Ito H., Hirata Y., Hiroe M., et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res. 69:1991;209-215.
5. Fujisaki H., Ito H., Hirata Y., et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest. 96:1995;1059-1065.
6. Ito H., Hirata Y., Adachi S., et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest. 92:1993;398-403.
7. Yamazaki T., Komuro I., Kudoh S., et al. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem. 271:1996;3221-3228.
8. Beyer M.E., Slesak G., Hoffmeister H.M. Significance of endothelin-B receptors for myocardial contractility and myocardial energy metabolism. J Pharmacol Exp Ther. 278:1996;1228-1234.
9. Margulies K.B., Hildebrand F.L., Lerman A., Perrella M.A., Burnett J.C. Jr. Increased endothelin in experimental heart failure. Circulation. 82:1990;2226-2230.
10. Sakai S., Miyauchi T., Sakurai T., et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: marked increase in endothelin-1 production in the failing heart. Circulation. 93:1996;1214-1222.
11. Rodeheffer R.J., Lerman A., Heublein D.M., Burnett J.C. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc. 67:1992;719-724.
12. McMurray J.J., Ray S.G., Abdullah I., Dargie H.J., Morton J.J. Plasma endothelin in chronic heart failure. Circulation. 85:1992;1374-1379.
13. Clavell A., Stingo A., Margulies K., et al. Physiological significance of endothelin: its role in congestive heart failure. Circulation. 87:(Suppl V):1993;V45-V50.
14. Mulder P., Richard V., Derumeaux G., et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 96:1997;1976-1982.
15. Fraccarollo D., Hu K., Galuppo P., Gaudron P., Ertl G. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation. 96:1997;3963-3973.
16. Moe G.W., Albernaz A., Naik G.O., Kirchengast M., Stewart D.J. Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure. Cardiovasc Res. 39:1998;571-579.
17. Kiowski W., Sütsch G., Hunziker P., et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
18. Meyrick B., Gamble W., Reid L. Development of Crotalaria pulmonary hypertension: hemodynamic and structural study. Am J Physiol. 239:1980;H692-H702.
19. Doggrell S.A., Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res. 39:1998;89-105.
20. Ceconi C., Condorelli E., Quinzanini M., et al. Noradrenaline, atrial natriuretic peptide, bombesin and neurotensin in myocardium and blood of rats in congestive cardiac failure. Cardiovasc Res. 23:1989;674-682.
21. Brunner F. Tissue endothelin-1 levels in perfused rat heart following stimulation with agonists and in ischaemia and reperfusion. J Mol Cell Cardiol. 27:1995;1953-1963.
22. Brunner F., Wascher T.C. Contribution of the endothelium to transcapillary insulin transport in rat isolated perfused hearts. Diabetes. 47:1998;1127-1134.
23. Wienen W., Kammermeier H. Intra- and extracellular markers in interstitial transudate of perfused rat hearts. Am J Physiol. 254:1988;H785-H794.
24. Schuller-Petrovic S., Siedler S., Kern T., et al. Imbalance between the endothelial cell-derived contracting factors prostacyclin and angiotensin II and nitric oxide/cyclic GMP in human primary varicosis. Br J Pharmacol. 122:1997;772-778.
25. Brunner F., Mouton R., Lochner A., Opie L.H. Defective stretch-induced release of antrial natriuretic peptide from aging hypertensive rat heart: possible role of inositol phosphate pathway. J Cardiovasc Pharmacol. 25:1995;168-176.
26. Comini L., Agnoletti G., Panzali A., et al. Elevation of ANP synthesis during congestive heart failure in rats treated with monocrotaline. Am J Physiol. 268:1995;H391-H398.
27. Miyauchi T., Yorikane R., Sakai S., et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res. 73:1993;887-897.
28. Haleen S., Schroeder R., Walker D., et al. Efficacy of CI-1020, an endothelin-A receptor antagonist, in hypoxic pulmonary hypertension. J Cardiovasc Pharmacol. 31:(Suppl. 1):1998;S331-S335.
29. A receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3-3-diphenyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther. 282:1997;1312-1318.
30. Ichikawa K.I., Hidai C., Okuda C., et al. Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium. J Am Coll Cardiol. 27:1996;1286-1291.
31. Hill N., Warburton R.R., Pietras L., Klinger J.R. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol. 83:1997;1209-1215.
32. Yorikane R., Sakai S., Miyauchi T., Sakurai T., Goto K. Possible involvement of endothelin-1 in cardiac hypertrophy. Arzneim-Forsch/Drug Res. 44:1994;412-415.
33. Mathew R., Zeballos G.A., Tun H., Gewitz M.H. Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats. Cardiovasc Res. 30:1995;739-746.
34. Okuda C. Enhanced endothelin-1 mRNA expression in the lung with monocrotaline-induced pulmonary hypertension. J Tokyo Wom Med Coll. 64:1994;1004-1011.
35. B-receptor mRNA in the lung of rats with pulmonary hypertension. J Cardiovasc Pharmacol. 22:(Suppl. 8):1993;S336-S338.
36. Takahashi T., Kanda T., Inoue M., et al. Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. Life Sci. 63:1998;PL137-PL143.
37. Suzuki T., Kumazaki T., Mitsui Y. Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun. 191:1993;823-830.
38. Tønnessen T., Giaid A., Saleh D., et al. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res. 76:1995;767-772.
39. Lindpaintner K., Jin M.W., Niedermaier N., Wilhelm M.J., Ganten D. Cardiac angiotensinogen and its local activation in the isolated perfused beating heart. Circ Res. 67:1990;564-573.
40. DeLannoy L.M., Danser A.H.J., Bouhuizen A.M.B., Saxena P.R., Schalekamp M.A.D.H. Localization and production of angiotensin II in the isolated perfused rat heart. Hypertension. 31:1998;1111-1117.
41. Van Gilst W.H., de Graefff P.A., Wesseling H., de Langen C.D. Reduction of reperfusion arrthythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol. 8:1986;722-728.
42. 1 receptor-mediated attenuation of cardiac hypertrophy due to volume overload: involvement of endothelin. Eur J Pharmacol. 280:1995;11-17.
43. Fukuda Y., Hirata Y., Yoshimi H., et al. Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes. Biochem Biophys Res Commun. 155:1988;167-172.
44. Mäntymaa P., Leppäluoto J., Ruskoaho H. Endothelin stimulates basal and stretch-induced atrial natriuretic peptide secretion from the perfused rat heart. Endocrinology. 126:1990;587-595.
45. Burnett J.C., Kao P.C., Hu D.C., et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 231:1986;1145-1147.
46. Matsubara H., Yamamoto J., Hirata Y., et al. Changes of atrial natriuretic peptide and its messenger RNA with development and regression of cardiac hypertrophy in renovascular hypertensive rats. Circ Res. 66:1990;176-184.
47. Franch H.A., Dixon R.A.F., Blaine E.H., Siegl P.K.S. Ventricular atrial natriuretic factor in the cardiomyopathic hamster model of congestive heart failure. Circ Res. 62:1988;31-36.
48. B receptor antagonist in heart failure. Cardiovasc Res. 39:1998;617-624.